Matches in Wikidata for { <http://www.wikidata.org/entity/Q60926780> ?p ?o ?g. }
- Q60926780 description "article scientifique publié en 2018" @default.
- Q60926780 description "artículu científicu espublizáu n'avientu de 2018" @default.
- Q60926780 description "im Dezember 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q60926780 description "scientific article published on 29 December 2018" @default.
- Q60926780 description "wetenschappelijk artikel" @default.
- Q60926780 description "наукова стаття, опублікована в грудні 2018" @default.
- Q60926780 name "Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial" @default.
- Q60926780 name "Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial" @default.
- Q60926780 type Item @default.
- Q60926780 label "Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial" @default.
- Q60926780 label "Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial" @default.
- Q60926780 prefLabel "Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial" @default.
- Q60926780 prefLabel "Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial" @default.
- Q60926780 P1433 Q60926780-D85BEEC8-441C-4495-85B0-A1BF21A5CF93 @default.
- Q60926780 P1476 Q60926780-45F83068-219D-4D7F-8E37-1C7A46CA19BA @default.
- Q60926780 P2093 Q60926780-044AC654-F68A-42E3-A3C1-CA18CE6248D6 @default.
- Q60926780 P2093 Q60926780-2CFDF4BA-9AAD-4A33-9B39-DAED958DB119 @default.
- Q60926780 P2093 Q60926780-494B7FD1-0342-494C-9745-EED88E41EFE1 @default.
- Q60926780 P2093 Q60926780-68C4DE26-D0E7-4287-A7FB-6F6395BF23E1 @default.
- Q60926780 P2093 Q60926780-6CC0ED4F-E78F-4D61-AD42-C4444D692DC2 @default.
- Q60926780 P2093 Q60926780-7A73822F-EAE7-41C2-B78E-2FD077B8BF36 @default.
- Q60926780 P2093 Q60926780-B2C594D3-D4DE-4AF0-958D-C778B9A56636 @default.
- Q60926780 P2860 Q60926780-1A3C88EB-3255-4337-9EAC-D7F9CBCE099D @default.
- Q60926780 P2860 Q60926780-1B15DD71-607F-407B-B7B2-7B3EA12589CA @default.
- Q60926780 P2860 Q60926780-2201197D-C60A-4387-8051-22AAC75339DE @default.
- Q60926780 P2860 Q60926780-270AEE2D-16F4-4F92-B50C-71383D8C7C94 @default.
- Q60926780 P2860 Q60926780-46EFDD8B-8312-421A-9109-8DCFB8EAE4D4 @default.
- Q60926780 P2860 Q60926780-6277AC22-4074-4DF9-8CB6-166CB7EC21C7 @default.
- Q60926780 P2860 Q60926780-65988650-3E7F-42C2-9FF6-2EF7435B0F1E @default.
- Q60926780 P2860 Q60926780-80CF4789-40F1-4BD2-912C-37CDEEEDB75D @default.
- Q60926780 P2860 Q60926780-87FCF3B8-FEAF-4B2C-AAC7-0068C76D121C @default.
- Q60926780 P2860 Q60926780-901D10CD-199F-4AEE-8278-C05D7528EC92 @default.
- Q60926780 P2860 Q60926780-9A480E2A-2B8D-47CA-998E-0C24C2F838EA @default.
- Q60926780 P2860 Q60926780-A8E200E0-DC46-4C46-9B79-0CC73C26AD70 @default.
- Q60926780 P2860 Q60926780-AB174833-EEF9-4303-BAD2-0DB73A028227 @default.
- Q60926780 P2860 Q60926780-B4EE9CBB-F0E2-462E-8F23-D70A20C094F1 @default.
- Q60926780 P2860 Q60926780-BB82E37D-13B8-4D12-BD4F-A3E363220AEC @default.
- Q60926780 P2860 Q60926780-D005BBE1-4A0C-43A5-8BF5-BD5A83E501AD @default.
- Q60926780 P2860 Q60926780-D66AD73F-A624-4C16-80FC-8825FD8AB48C @default.
- Q60926780 P2860 Q60926780-E1FEB363-123E-4BA0-8E7F-5C7832F5115D @default.
- Q60926780 P2860 Q60926780-F21DB493-D9B0-444D-B16B-A6884BCAA39D @default.
- Q60926780 P2860 Q60926780-FA3C26E0-137F-4F12-B6CB-00F66F2B9AC3 @default.
- Q60926780 P2888 Q60926780-A622B603-991F-4AB2-8ECA-E551AFE0397B @default.
- Q60926780 P304 Q60926780-0FA3D0C4-C80A-45DF-9ED3-55CD76984730 @default.
- Q60926780 P31 Q60926780-06B5D8E4-6370-405E-A3DF-876409E313B7 @default.
- Q60926780 P356 Q60926780-F4B37BC8-5BC7-467E-B2EC-955678542FA6 @default.
- Q60926780 P407 Q60926780-BA0F6959-C346-414B-8BA5-D38936FED37F @default.
- Q60926780 P433 Q60926780-D365241C-E978-4227-839C-366A61651C41 @default.
- Q60926780 P478 Q60926780-906B529E-5A67-445E-BB8E-49FE82ED44F2 @default.
- Q60926780 P50 Q60926780-0B69E725-3322-4C51-87C3-EF7D1FA7F04E @default.
- Q60926780 P50 Q60926780-26EC887D-03EA-48C4-8EAD-10B5CA9C0DB2 @default.
- Q60926780 P577 Q60926780-293A0F29-F8F2-46D4-8483-8997A18BA529 @default.
- Q60926780 P6179 Q60926780-10692C5F-8324-400B-A78F-7EF894B1E1EC @default.
- Q60926780 P698 Q60926780-FDAABBB7-2545-42C6-B534-9FA9E5642907 @default.
- Q60926780 P921 Q60926780-0C020D9D-F409-453B-A86E-4D11D4F2EA78 @default.
- Q60926780 P921 Q60926780-0ED1EAFD-D506-4B54-9A50-EDA0FF18D8A7 @default.
- Q60926780 P921 Q60926780-5AB7DD03-ACAB-4499-AC03-261948914152 @default.
- Q60926780 P921 Q60926780-91EA0DB0-01E9-4989-94C1-D56CF10B074B @default.
- Q60926780 P921 Q60926780-A50E2D8A-E7CE-40A5-A4CC-D54535FDE8D0 @default.
- Q60926780 P921 Q60926780-E9CF80FA-72BD-4E49-90F8-6E28B826B00E @default.
- Q60926780 P921 Q60926780-F84A879F-E6B5-4520-9B06-58128732E8D5 @default.
- Q60926780 P932 Q60926780-732A6A84-9CD0-48D7-83A1-DAB0543B2B03 @default.
- Q60926780 P356 S13063-018-3105-6 @default.
- Q60926780 P698 30594222 @default.
- Q60926780 P1433 Q7840023 @default.
- Q60926780 P1476 "Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial" @default.
- Q60926780 P2093 "Atsushi Kawakami" @default.
- Q60926780 P2093 "Chizu Fukushima" @default.
- Q60926780 P2093 "Hiroshi Yamamoto" @default.
- Q60926780 P2093 "Junya Miyamoto" @default.
- Q60926780 P2093 "Kumiko Arinaga" @default.
- Q60926780 P2093 "Naoko Hagimori" @default.
- Q60926780 P2093 "Yurika Kawazoe" @default.
- Q60926780 P2860 Q24614759 @default.
- Q60926780 P2860 Q28300546 @default.
- Q60926780 P2860 Q30956847 @default.
- Q60926780 P2860 Q36247836 @default.
- Q60926780 P2860 Q36838115 @default.
- Q60926780 P2860 Q37808103 @default.
- Q60926780 P2860 Q38072250 @default.
- Q60926780 P2860 Q38759360 @default.
- Q60926780 P2860 Q40040817 @default.
- Q60926780 P2860 Q40157162 @default.
- Q60926780 P2860 Q40171678 @default.
- Q60926780 P2860 Q40172573 @default.
- Q60926780 P2860 Q40420676 @default.
- Q60926780 P2860 Q40522265 @default.
- Q60926780 P2860 Q51025492 @default.
- Q60926780 P2860 Q53662300 @default.
- Q60926780 P2860 Q54675737 @default.
- Q60926780 P2860 Q55049410 @default.
- Q60926780 P2860 Q74309346 @default.
- Q60926780 P2860 Q86513694 @default.
- Q60926780 P2888 s13063-018-3105-6 @default.
- Q60926780 P304 "715" @default.
- Q60926780 P31 Q13442814 @default.
- Q60926780 P356 "10.1186/S13063-018-3105-6" @default.
- Q60926780 P407 Q1860 @default.
- Q60926780 P433 "1" @default.
- Q60926780 P478 "19" @default.